NCT02054689
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Radiation therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patient must have at least 1 lesion which must be a minimum of 3cm in greatest dimension & no larger than 5cm; Lesions must be suitable for treatment by fractionated stereotactic radiosurgery
Exclusions: Patient with prior radiotherapy or surgical resection to the brain; Patients with more than 4 brain lesions
https://ClinicalTrials.gov/show/NCT02054689